<DOC>
	<DOCNO>NCT01450384</DOCNO>
	<brief_summary>This phase I trial study side effect best dose give pemetrexed disodium sorafenib tosylate together treat patient advance solid tumor . Pemetrexed disodium sorafenib tosylate may stop growth tumor cell block enzymes need cell growth . Sorafenib tosylate may also stop growth solid tumor block blood flow tumor . Giving pemetrexed disodium together sorafenib tosylate may kill tumor cell .</brief_summary>
	<brief_title>Pemetrexed Disodium Sorafenib Tosylate Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine dos combination pemetrexed ( pemetrexed disodium ) sorafenib ( sorafenib tosylate ) appropriate Phase II study . SECONDARY OBJECTIVES : I . To evaluate safety , tolerance , toxicity combination pemetrexed sorafenib . II . To observe antitumor effect combination . OUTLINE : This dose-escalation study pemetrexed disodium sorafenib tosylate . Patients receive pemetrexed disodium intravenously ( IV ) day 1 every 2 week sorafenib tosylate orally ( PO ) twice daily ( BID ) day 1-5 . Courses repeat every 4 week absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Advanced solid tumor malignancy potentially curative treatment ; limit number prior line therapy Performance status Eastern Cooperative Oncology Group ( ECOG ) equal less 1 Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) = &lt; 3 x upper institutional limit ( ULN ) Total bilirubin = &lt; 1.5 ULN Creatinine clearance ( CrCl ) &gt; = 45 mL/min measure standard CockcroftGault equation International normalize ratio ( INR ) = &lt; 1.5 ( due anticoagulant ) White blood cell count ( WBC ) &gt; = 3,000 cells/mm3 Absolute neutrophil count ( ANC ) &gt; = 1,500 cells/mm3 Platelets &gt; = 100,000 cells/mm3 Hemoglobin ( Hgb ) &gt; = 8.5 g/dL Prior toxicity allow long stable would interfere study drug toxicity assessment Measurable evaluable disease Response Evaluation Criteria In Solid Tumors ( RECIST ) ( v 1.1 ) Ability understand willingness sign write informed consent document ; sign informed consent must obtain prior study specific procedure Women childbearing potential must negative pregnancy test perform within 7 day prior start treatment ; woman childbearing potential men must agree use medically accept form birth control duration study participation ; men must agree use medically accept form birth control 2 month follow completion study treatment Any investigational agent within 4 week first dose study treatment Unwillingness inability take folic acid , vitamin B12 , dexamethasone Known presume intolerance pemetrexed sorafenib ; unable swallow medication ; suspect malabsorption Active illicit substance alcohol abuse Contraindication antiangiogenic agent , include : Pulmonary hemorrhage/bleeding event &gt; = Grade 2 within 4 week less prior first dose study drug Any hemorrhage/bleeding event &gt; = Grade 3 within 4 week less prior first dose study drug Serious nonhealing wound , ulcer , bone fracture Thrombolic embolic event myocardial infarction , cerebrovascular accident include transient ischemic attack within past 6 month Major cardiac dysfunction , uncontrolled angina , congestive heart failure New York Heart Association ( NYHA ) class III high , ventricular arrhythmia require antiarrhythmic therapy Systolic blood pressure &gt; 160 mmHg diastolic pressure &gt; 100 mmHg despite optimal medical management Inability interrupt aspirin nonsteroidal antiinflammatory agent 5 day period Serious uncontrolled infection &gt; Common Terminology Criteria Adverse Events ( CTCAE ) ( v 4 ) grade 2 Peripheral motor sensory neuropathy &gt; CTCAE ( v4 ) grade 2 Uncontrolled metastatic brain disease Serum B12 folate level institution 's low limit normal . Patients may begin B12/folic acid supplementation reconsider study level meet eligibility requirement Administration nonsteroidal antiinflammatory drug ( NSAIDs ) within 5 day prior pemetrexed dosing ( note : candidate routinely take NSAIDs prior enrollment , consider transition alternate nonNSAID duration study treatment , possible ) . Other condition ( ) opinion investigator might compromise objective study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>protocol specific</keyword>
</DOC>